Talphera Inc (NASDAQ: TLPH) is a clinical-stage pharmaceutical company focused on developing drug candidates for pain management. The company has no product revenue from its lead pipeline asset; its limited historical cash flows derived from a marketing services arrangement tied to DSUVIA, a previously commercialized opioid analgesic sold to the U.S. Department of Defense by licensee Alora Pharmaceuticals. In January 2024, Talphera monetized its rights to future DSUVIA-related payments by selling them to XOMA (US) LLC, using the proceeds to fund development of its lead product candidate, Niyad. Alora discontinued non-DoD DSUVIA sales in October 2024 and subsequently filed to withdraw the DSUVIA NDA with the FDA, effectively ending that revenue stream. The company has incurred recurring operating losses and negative cash flows since inception. As of the 10-K filed March 23, 2026, auditors have issued a going-concern qualification for the fiscal year ended December 31, 2025. CEO Vincent J. Angotti and CFO Raffi Asadorian lead the company.

Revenue model

Talphera has no product revenue from its pipeline. Historical cash receipts came from marketing support services tied to DSUVIA sales to the DoD under a marketing agreement with Alora. In January 2024, those future payment rights were sold to XOMA, recorded as debt on Talphera's balance sheet. With Alora's DSUVIA discontinuation and NDA withdrawal request, this revenue stream has effectively ceased.

Products and services

Lead product candidate: Niyad (clinical-stage, specific indication not detailed in excerpts). Historical commercial product: DSUVIA (sufentanil sublingual tablet), commercialized by Alora Pharmaceuticals for DoD use; Alora filed to withdraw the DSUVIA NDA as of 2025. 'Fedsyra' is a registered trademark of Talphera.

Customers and end markets

End market: U.S. Department of Defense, as the buyer for DSUVIA inventory held by Alora. No other customer segments disclosed in the filing excerpts.

Value-chain role

Clinical-stage drug developer. Talphera licenses commercial rights to third parties (Alora) and receives milestone and service payments rather than selling directly to end customers. Subject to FDA regulatory approval requirements and HIPAA/HITECH compliance obligations.

Geographic exposure

Primary operations in the United States. Filing references EU GDPR compliance obligations, indicating some potential international data-handling exposure, but no international commercial operations are described.

Source: SEC 10-K, filed 2026-03-23

Industry: Pharmaceutical Preparations Peers: Elicio Therapeutics Inc Real Brands, Inc. Hepion Pharmaceuticals Inc Elite Pharmaceuticals Inc Processa Pharmaceuticals Inc Johnson & Johnson NVN Liquidation, Inc. Nutriband Inc Reviva Pharmaceuticals Holdings Inc